- Home
- ETJ vs PHAR Comparison
ETJ vs PHAR Comparison
Compare ETJ & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETJ
- PHAR
- Stock Information
- Founded
- ETJ 2007
- PHAR 1988
- Country
- ETJ United States
- PHAR Netherlands
- Employees
- ETJ N/A
- PHAR N/A
- Industry
- ETJ Finance Companies
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- ETJ Finance
- PHAR Health Care
- Exchange
- ETJ Nasdaq
- PHAR Nasdaq
- Market Cap
- ETJ 623.9M
- PHAR 618.3M
- IPO Year
- ETJ N/A
- PHAR N/A
- Fundamental
- Price
- ETJ $9.20
- PHAR $8.20
- Analyst Decision
- ETJ
- PHAR Strong Buy
- Analyst Count
- ETJ 0
- PHAR 3
- Target Price
- ETJ N/A
- PHAR $27.00
- AVG Volume (30 Days)
- ETJ 175.6K
- PHAR 5.6K
- Earning Date
- ETJ 01-01-0001
- PHAR 03-13-2025
- Dividend Yield
- ETJ 8.30%
- PHAR N/A
- EPS Growth
- ETJ N/A
- PHAR N/A
- EPS
- ETJ N/A
- PHAR N/A
- Revenue
- ETJ N/A
- PHAR $285,745,000.00
- Revenue This Year
- ETJ N/A
- PHAR $20.08
- Revenue Next Year
- ETJ N/A
- PHAR $9.22
- P/E Ratio
- ETJ N/A
- PHAR N/A
- Revenue Growth
- ETJ N/A
- PHAR 30.64
- 52 Week Low
- ETJ $7.20
- PHAR $6.65
- 52 Week High
- ETJ $8.47
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- ETJ 44.49
- PHAR 36.29
- Support Level
- ETJ $9.08
- PHAR $8.49
- Resistance Level
- ETJ $9.35
- PHAR $9.35
- Average True Range (ATR)
- ETJ 0.11
- PHAR 0.55
- MACD
- ETJ -0.00
- PHAR -0.17
- Stochastic Oscillator
- ETJ 30.00
- PHAR 12.14
About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.